Cells and mice
The 2015 paper identified MOTS-c and reported effects on insulin sensitivity and metabolic homeostasis in mouse models. [1]
Compound evidence dossier · C-019
MOTS-c: mitochondrial claims and evidence
A mitochondrial-derived peptide linked to metabolism and longevity stories. The intervention evidence remains preclinical, with no established human treatment outcome.
What does the evidence say?
MOTS-c has interesting cell and animal evidence, but no reliable human trial shows that injected synthetic MOTS-c improves weight, insulin sensitivity, exercise capacity or lifespan. Studies measuring the body’s own circulating MOTS-c are not treatment trials. The FDA reported that it found no human exposure data for drug products containing MOTS-c, leaving efficacy and safety unresolved.
Claim check
Which claims survive an evidence check?
Each row keeps the claim, its best supporting evidence and the limiting caveat together.
MOTS-c improves metabolic health in humansNot demonstrated
The foundational treatment findings came from cells and mice. Human observational work has measured endogenous MOTS-c, but that does not show that administering synthetic peptide improves a clinical outcome.
It acts like exercisePreclinical shorthand
Animal and mechanistic findings prompted the “exercise mimetic” label. The phrase should not be translated into proven human fitness, recovery or disease-prevention effects.
It is a longevity peptideUnsupported outcome
No human intervention trial establishes longer life or delayed age-related disease. Longevity language runs well beyond the available evidence.
A natural human peptide must be safe to injectFalse inference
A molecule produced in the body is not automatically safe when synthesised, formulated and administered as a drug. Route, concentration, impurities, aggregation and immune response all matter.
Human evidence
What have studies in people shown?
The evidence stack is heavily weighted towards discovery biology. The gap is not a small missing detail; it is the absence of a human treatment programme that measures the marketed outcomes.
Endogenous levels are not a drug trial
Some studies relate circulating MOTS-c to exercise or disease markers. They measure a peptide produced by the body and cannot establish what an injected product does.
No identified human drug exposure data
The FDA’s 2026 review found no human studies using compounded MOTS-c drug substance and no adequate evidence of effectiveness or human safety. [2] [3]
Critical distinction
Why a mitochondrial mechanism does not establish a longevity treatment
Mechanisms generate hypotheses. A longevity claim needs controlled human outcomes, long follow-up and a clear account of harms.
- What is established
- MOTS-c is a mitochondrial-derived peptide studied in metabolic signalling.
- What is preclinical
- Reported treatment effects on insulin resistance, obesity and physical capacity come mainly from laboratory and animal models.
- What human studies often measure
- Associations involving endogenous circulating MOTS-c, not outcomes after a verified synthetic drug product.
- What is missing
- A dependable human dose-response, clinical benefit, long-term safety and product-quality standard for marketed vials.
Risk register
What could go wrong?
There is no human treatment dataset large enough to define expected adverse effects. The absence of reported harm in a missing dataset is not evidence of safety.
| Risk channel | Evidence-aware interpretation |
|---|---|
| Human drug safety | The FDA found no human exposure data for drug products containing MOTS-c. Expected adverse-event rates are unknown. |
| Product characterisation | The regulator identified complexity involving aggregation, impurities and active-ingredient characterisation. |
| Biological uncertainty | Changing metabolic signalling may have effects outside the intended pathway. Human off-target effects and interactions are not mapped. |
| Market-product uncertainty | A label, purity result or sequence statement cannot provide missing clinical safety, sterility or stability evidence. |
Product evidence
What would evidence about a vial prove?
A compound-level literature verdict and a product-level finding answer different questions. Neither can substitute for the other.
Claimed compound
The literature applies only if the vial contains the same active substance and form that the source studied.
Label and release record
A batch-specific record should identify the material, method, result, specification and accountable laboratory.
Submitted sample
A defensible result concerns the sample tested. It does not certify every vial, future batch or storage condition.
Clinical meaning
Identity, purity and sterility evidence cannot establish a health outcome or fill a missing human safety dataset.
Status check
Is it authorised or prohibited?
Medicine authorisation, lawful supply and anti-doping status are separate checks. Each can change and should be verified at the point of decision.
| System | Finding checked 8 August 2026 |
|---|---|
| UK medicine status | No MOTS-c medicine with a UK marketing authorisation was identified in the MHRA public database check. |
| United States | MOTS-c is not an FDA-approved medicine. The FDA’s 2026 advisory assessment found inadequate characterisation and no support for effectiveness or human safety. |
| Sport | MOTS-c is included on the 2026 WADA Prohibited List. Athletes should treat it as prohibited at all times and verify the current list and their governing rules. |
Method note
How was this judgement made?
We separated administered synthetic MOTS-c from studies of naturally circulating MOTS-c. Cell and animal intervention findings were not described as human treatment evidence.
Searches prioritised regulator documents, current medicine and anti-doping records, trial registrations and indexed primary studies. Seller pages were not used as evidence of efficacy or safety.
Read the full editorial method and inspect the evidence library.
Source ledger
Primary sources
- Lee et al., discovery and preclinical metabolic study of MOTS-cCell and animal research; not a human intervention trial. Checked 8 August 2026.
- US FDA, MOTS-c physicochemical characterisation briefing, 2026Substance characterisation, aggregation and impurity assessment. Checked 8 August 2026.
- US FDA, MOTS-c clinical and regulatory presentation, July 2026No identified human drug exposure, effectiveness support or human safety evidence. Checked 8 August 2026.
- US FDA, Certain Bulk Drug Substances That May Present Significant Safety RisksCurrent regulator summary of characterisation, impurity, immunogenicity and safety concerns. Checked 8 August 2026.
- World Anti-Doping Agency, 2026 Prohibited ListCurrent list used for sport-status checks; effective 1 January 2026. Checked 8 August 2026.
- MHRA ProductsPublic UK medicines database used for the marketing-authorisation check. Checked 8 August 2026.
Questions answered
Frequently asked questions
Short answers keep the decisive caveat beside the claim.
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and studied as a metabolic signalling molecule. Its biology is an active research area; that does not make marketed injections established treatments.
Has injected MOTS-c been tested in humans?
The FDA’s 2026 review found no human exposure data for drug products containing MOTS-c. Human studies of naturally circulating MOTS-c or exercise-related levels are not injection trials.
Does MOTS-c cause weight loss?
No reliable human intervention evidence establishes weight loss from synthetic MOTS-c. The often-cited metabolic and obesity findings come from mouse studies.
Is MOTS-c a longevity treatment?
No human trial shows that MOTS-c extends life or prevents age-related disease. The longevity claim is an extrapolation from mechanisms and preclinical models.
Is MOTS-c prohibited in sport?
Yes. MOTS-c is included on the 2026 WADA Prohibited List. Athletes should verify current status through the official list, Global DRO and their anti-doping organisation.
Does a high-purity result make MOTS-c safe?
No. Purity is one analytical property of one sample. It does not establish sterility, dose accuracy, stability, immune risk, human efficacy or long-term safety.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item C-019, MOTS-c: mitochondrial claims and evidence was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 9 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.